Abstract
e15562 Background: Outcome analysis of GTN patients treated by a single gynecologic oncologist. Methods: A review of all patients with GTN treated from 1983-2009 by a single gynecologic oncologist who prospectively collected their demographic and clinical data. Results: 31 (78%) of 40 patients had a WHO score <7 and received single agent methotrexate (MTX) as primary therapy. All but one received MTX 0.4 mg/kg. daily for 5 days every 21 days (mean number of cycles, 3; 80% remission). Of 9 (22%) high-risk patients (WHO score > 6), 6 received MTX, actinomycin D, cyclophosphamide (MAC) (33% remission), and 3 received etoposide, MTX, actinomycin D, (EMA), and vincristine, cyclophosphamide or EMA and cisplatin, etoposide (67% remission). All MAC failures died of GTN. Overall, 35 of the 40 patients (87.5%) achieved a sustained remission. Conclusions: A 5-day MTX regimen given every 21 days is a convenient, well-tolerated and effective for patients with low-risk GTN. High-risk patients should receive an aggressive first line regimen such as EMA/CO. No significant financial relationships to disclose.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call